Showing results (391-400 of 861) with videos related to

Sort By:
Pageof 87
Lupus Science & Medicine|January 8, 2019
Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Lupus Science & Medicine|May 21, 2021
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus expertsJohanna Mucke, Marta Alarcon-Riquelme, Jeanette Andersen, et al.
Lupus Science & Medicine|May 6, 2021
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy-a tertiary centre experience in an Appalachian stateElise Danielle McVeigh, Amna Batool, Arnold Stromberg, et al.
Lupus Science & Medicine|June 18, 2020
Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosusFabien B Vincent, Rangi Kandane-Rathnayake, Rachel Koelmeyer, et al.
Lupus Science & Medicine|August 8, 2022
Truncated isoforms of GPSM2 containing the GoLoco motif region promote CD4+ T-cell migration in SLERuth L Esser, Carolin Brück, Jan Thiele, et al.
Lupus Science & Medicine|September 15, 2021
Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015Miao Jiang, Aimee M Near, Barnabas Desta, et al.
Lupus Science & Medicine|May 15, 2015
Patients with overlap autoimmune disease differ from those with 'pure' diseaseMichael D Lockshin, Alana B Levine, Doruk Erkan
Lupus Science & Medicine|May 7, 2020
Cell-bound complement activation products associate with lupus severity in SLECristina Arriens, Roberta Vezza Alexander, Sonali Narain, et al.
Lupus Science & Medicine|April 29, 2020
Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr miceKaren A Fortner, Luz P Blanco, Iwona Buskiewicz, et al.
Lupus Science & Medicine|May 14, 2020
Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trialAnca D Askanase, Enxu Zhao, Julie Zhu, et al.
Pageof 87